O	0	4	Gene	Gene	NN	B-NP
O	5	13	transfer	transfer	NN	I-NP
O	14	16	of	of	IN	B-PP
O	17	22	naked	naked	JJ	B-NP
O	23	26	DNA	DNA	NN	I-NP
O	27	35	encoding	encode	VBG	B-VP
O	36	39	for	for	IN	B-PP
O	40	45	three	three	CD	B-NP
O	46	54	isoforms	isoform	NNS	I-NP
O	55	57	of	of	IN	B-PP
O	58	66	vascular	vascular	JJ	B-NP
O	67	78	endothelial	endothelial	JJ	I-NP
O	79	85	growth	growth	NN	I-NP
O	86	92	factor	factor	NN	I-NP
O	93	103	stimulates	stimulate	VBZ	B-VP
B-Multi-tissue_structure	104	114	collateral	collateral	JJ	B-NP
O	115	126	development	development	NN	I-NP
O	127	129	in	in	FW	B-ADVP
O	130	134	vivo	vivo	FW	I-ADVP
O	134	135	.	.	.	O

O	136	144	Vascular	Vascular	JJ	B-NP
O	145	156	endothelial	endothelial	JJ	I-NP
O	157	163	growth	growth	NN	I-NP
O	164	170	factor	factor	NN	I-NP
O	171	172	(	(	(	O
O	172	176	VEGF	VEGF	NN	B-NP
O	176	177	)	)	)	O
O	178	180	is	be	VBZ	B-VP
O	181	182	a	a	DT	B-NP
O	183	192	naturally	naturally	RB	I-NP
O	193	201	secreted	secrete	VBN	I-NP
B-Cell	202	213	endothelial	endothelial	JJ	I-NP
I-Cell	214	218	cell	cell	NN	I-NP
O	218	219	-	-	HYPH	B-NP
O	219	227	specific	specific	JJ	I-NP
O	228	235	mitogen	mitogen	NN	I-NP
O	235	236	.	.	.	O

O	237	239	We	We	PRP	B-NP
O	240	252	investigated	investigate	VBD	B-VP
O	253	256	the	the	DT	B-NP
O	257	267	hypothesis	hypothesis	NN	I-NP
O	268	272	that	that	IN	B-SBAR
O	273	278	naked	naked	JJ	B-NP
O	279	282	DNA	DNA	NN	I-NP
O	283	291	encoding	encode	VBG	B-VP
O	292	295	for	for	IN	B-PP
O	296	300	VEGF	VEGF	NN	B-NP
O	301	306	could	could	MD	B-VP
O	307	309	be	be	VB	I-VP
O	310	314	used	use	VBN	I-VP
O	315	317	in	in	IN	B-PP
O	318	319	a	a	DT	B-NP
O	320	328	strategy	strategy	NN	I-NP
O	329	331	of	of	IN	B-PP
B-Multi-tissue_structure	332	340	arterial	arterial	JJ	B-NP
O	341	345	gene	gene	NN	I-NP
O	346	353	therapy	therapy	NN	I-NP
O	354	356	to	to	TO	B-VP
O	357	366	stimulate	stimulate	VB	I-VP
B-Multi-tissue_structure	367	377	collateral	collateral	JJ	B-NP
I-Multi-tissue_structure	378	384	artery	artery	NN	I-NP
O	385	396	development	development	NN	I-NP
O	396	397	.	.	.	O

B-Cellular_component	398	405	Plasmid	Plasmid	NN	B-NP
O	406	409	DNA	DNA	NN	I-NP
O	410	418	encoding	encode	VBG	B-VP
O	419	423	each	each	DT	B-NP
O	424	426	of	of	IN	B-PP
O	427	430	the	the	DT	B-NP
O	431	436	three	three	CD	I-NP
O	437	446	principal	principal	JJ	I-NP
O	447	452	human	human	JJ	I-NP
O	453	457	VEGF	VEGF	NN	I-NP
O	458	466	isoforms	isoform	NNS	I-NP
O	467	468	(	(	(	O
O	468	477	phVEGF121	phVEGF121	NN	B-NP
O	477	478	,	,	,	O
O	479	488	phVEGF165	phVEGF165	NN	B-NP
O	488	489	,	,	,	O
O	490	492	or	or	CC	O
O	493	502	phVEGF189	phVEGF189	NN	B-NP
O	502	503	)	)	)	O
O	504	507	was	be	VBD	B-VP
O	508	515	applied	apply	VBN	I-VP
O	516	518	to	to	TO	B-PP
O	519	522	the	the	DT	B-NP
O	523	531	hydrogel	hydrogel	NN	I-NP
O	532	539	polymer	polymer	NN	I-NP
O	540	547	coating	coating	NN	I-NP
O	548	550	of	of	IN	B-PP
O	551	553	an	an	DT	B-NP
O	554	565	angioplasty	angioplasty	JJ	I-NP
O	566	573	balloon	balloon	NN	I-NP
O	574	577	and	and	CC	O
O	578	587	delivered	deliver	VBN	B-VP
B-Immaterial_anatomical_entity	588	602	percutaneously	percutaneously	RB	B-ADVP
O	603	605	to	to	TO	B-PP
O	606	609	one	one	CD	B-NP
B-Multi-tissue_structure	610	615	iliac	iliac	JJ	I-NP
I-Multi-tissue_structure	616	622	artery	artery	NN	I-NP
O	623	625	of	of	IN	B-PP
O	626	633	rabbits	rabbit	NNS	B-NP
O	634	638	with	with	IN	B-PP
O	639	650	operatively	operatively	RB	B-NP
O	651	658	induced	induce	VBN	I-NP
B-Organism_subdivision	659	667	hindlimb	hindlimb	NN	I-NP
O	668	676	ischemia	ischemia	NN	I-NP
O	676	677	.	.	.	O

O	678	686	Compared	Compare	VBN	B-PP
O	687	691	with	with	IN	B-PP
O	692	699	control	control	NN	B-NP
O	700	707	animals	animal	NNS	I-NP
O	708	719	transfected	transfecte	VBN	B-VP
O	720	724	with	with	IN	B-PP
O	725	729	LacZ	LacZ	NN	B-NP
O	729	730	,	,	,	O
O	731	735	site	site	NN	B-NP
O	735	736	-	-	HYPH	B-NP
O	736	744	specific	specific	JJ	I-NP
O	745	757	transfection	transfection	NN	I-NP
O	758	760	of	of	IN	B-PP
O	761	767	phVEGF	phVEGF	NN	B-NP
O	768	776	resulted	result	VBD	B-VP
O	777	779	in	in	IN	B-PP
O	780	789	augmented	augmented	JJ	B-NP
B-Multi-tissue_structure	790	800	collateral	collateral	JJ	I-NP
I-Multi-tissue_structure	801	807	vessel	vessel	NN	I-NP
O	808	819	development	development	NN	I-NP
O	820	830	documented	document	VBN	B-VP
O	831	833	by	by	IN	B-PP
O	834	840	serial	serial	JJ	B-NP
O	841	852	angiography	angiography	NN	I-NP
O	852	853	,	,	,	O
O	854	857	and	and	CC	O
O	858	869	improvement	improvement	NN	B-NP
O	870	872	in	in	IN	B-PP
B-Organism_substance	873	877	calf	calf	NN	B-NP
I-Organism_substance	878	883	blood	blood	NN	I-NP
O	884	892	pressure	pressure	NN	I-NP
O	893	898	ratio	ratio	NN	I-NP
O	899	900	(	(	(	O
O	900	908	ischemic	ischemic	JJ	B-ADJP
O	909	911	to	to	TO	B-PP
O	912	918	normal	normal	JJ	B-NP
B-Organism_subdivision	919	923	limb	limb	NN	I-NP
O	923	924	)	)	)	O
O	924	925	,	,	,	O
O	926	933	resting	rest	VBG	B-NP
O	934	937	and	and	CC	I-NP
O	938	945	maximum	maximum	JJ	I-NP
B-Organism_substance	946	951	blood	blood	NN	I-NP
O	952	956	flow	flow	NN	I-NP
O	956	957	,	,	,	O
O	958	961	and	and	CC	O
B-Tissue	962	971	capillary	capillary	NN	B-NP
O	972	974	to	to	TO	B-PP
B-Cell	975	982	myocyte	myocyte	NN	B-NP
O	983	988	ratio	ratio	NN	I-NP
O	988	989	.	.	.	O

O	990	997	Similar	Similar	JJ	B-NP
O	998	1005	results	result	NNS	I-NP
O	1006	1010	were	be	VBD	B-VP
O	1011	1019	obtained	obtain	VBN	I-VP
O	1020	1024	with	with	IN	B-PP
O	1025	1034	phVEGF121	phVEGF121	NN	B-NP
O	1034	1035	,	,	,	O
O	1036	1045	phVEGF165	phVEGF165	NN	B-NP
O	1045	1046	,	,	,	O
O	1047	1050	and	and	CC	O
O	1051	1060	phVEGF189	phVEGF189	NN	B-NP
O	1060	1061	,	,	,	O
O	1062	1067	which	which	WDT	B-NP
O	1068	1076	suggests	suggest	VBZ	B-VP
O	1077	1081	that	that	IN	B-SBAR
O	1082	1087	these	these	DT	B-NP
O	1088	1096	isoforms	isoform	NNS	I-NP
O	1097	1100	are	be	VBP	B-VP
O	1101	1113	biologically	biologically	RB	B-ADJP
O	1114	1124	equivalent	equivalent	JJ	I-ADJP
O	1125	1129	with	with	IN	B-PP
O	1130	1137	respect	respect	NN	B-NP
O	1138	1140	to	to	TO	B-PP
O	1141	1143	in	in	FW	B-NP
O	1144	1148	vivo	vivo	FW	I-NP
O	1149	1161	angiogenesis	angiogenesis	NN	I-NP
O	1161	1162	.	.	.	O

O	1163	1166	The	The	DT	B-NP
O	1167	1171	fact	fact	NN	I-NP
O	1172	1176	that	that	IN	B-SBAR
O	1177	1182	viral	viral	JJ	B-NP
O	1183	1185	or	or	CC	I-NP
O	1186	1191	other	other	JJ	I-NP
O	1192	1202	adjunctive	adjunctive	JJ	I-NP
O	1203	1210	vectors	vector	NNS	I-NP
O	1211	1215	were	be	VBD	B-VP
O	1216	1219	not	not	RB	I-VP
O	1220	1228	required	require	VBN	I-VP
O	1229	1236	further	further	RBR	B-ADVP
O	1237	1245	suggests	suggest	VBZ	B-VP
O	1246	1250	that	that	IN	B-SBAR
O	1251	1259	secreted	secrete	VBN	B-NP
O	1260	1264	gene	gene	NN	I-NP
O	1265	1273	products	product	NNS	I-NP
O	1274	1277	may	may	MD	B-VP
O	1278	1282	have	have	VB	I-VP
O	1283	1292	potential	potential	JJ	B-NP
O	1293	1304	therapeutic	therapeutic	JJ	I-NP
O	1305	1312	utility	utility	NN	I-NP
O	1313	1317	even	even	RB	B-ADVP
O	1318	1322	when	when	WRB	I-ADVP
O	1323	1326	the	the	DT	B-NP
O	1327	1333	number	number	NN	I-NP
O	1334	1336	of	of	IN	B-PP
O	1337	1349	successfully	successfully	RB	B-NP
O	1350	1361	transfected	transfecte	VBN	I-NP
B-Cell	1362	1367	cells	cell	NNS	I-NP
O	1368	1375	remains	remain	VBZ	B-VP
O	1376	1379	low	low	JJ	B-ADJP
O	1379	1380	.	.	.	O

B-Multi-tissue_structure	1381	1389	Arterial	Arterial	JJ	B-NP
O	1390	1394	gene	gene	NN	I-NP
O	1395	1403	transfer	transfer	NN	I-NP
O	1404	1406	of	of	IN	B-PP
O	1407	1412	naked	naked	JJ	B-NP
O	1413	1416	DNA	DNA	NN	I-NP
O	1417	1425	encoding	encode	VBG	B-VP
O	1426	1429	for	for	IN	B-PP
O	1430	1431	a	a	DT	B-NP
O	1432	1440	secreted	secrete	VBN	I-NP
O	1441	1451	angiogenic	angiogenic	JJ	I-NP
O	1452	1460	cytokine	cytokine	NN	I-NP
O	1460	1461	,	,	,	O
O	1462	1466	thus	thus	RB	B-ADVP
O	1466	1467	,	,	,	O
O	1468	1478	represents	represent	VBZ	B-VP
O	1479	1480	a	a	DT	B-NP
O	1481	1490	potential	potential	JJ	I-NP
O	1491	1502	alternative	alternative	NN	I-NP
O	1503	1505	to	to	TO	B-PP
O	1506	1517	recombinant	recombinant	JJ	B-NP
O	1518	1525	protein	protein	NN	I-NP
O	1526	1540	administration	administration	NN	I-NP
O	1541	1544	for	for	IN	B-PP
O	1545	1556	stimulating	stimulate	VBG	B-VP
B-Multi-tissue_structure	1557	1567	collateral	collateral	JJ	B-NP
I-Multi-tissue_structure	1568	1574	vessel	vessel	NN	I-NP
O	1575	1586	development	development	NN	I-NP
O	1586	1587	.	.	.	O

